Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study findsOzempic can reduce metabolic risks in schizophrenia patients, multicenter study finds
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA Psychiatry. Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a Read More
STAT+: Driven by GLP-1s, prescription drug spending explodes at major health insurersSTAT+: Driven by GLP-1s, prescription drug spending explodes at major health insurers
Health insurance companies have lamented fast-rising medical expenses for more than two years. This year is no different as Americans continue to get more care than insurers expected. One of the main culprits of that higher spending: prescription drugs, and GLP-1s in particular. Some insurers spent more on drugs in the first nine months of Read More
Tai Chi for Insomnia; WHO Guidance on GLP-1 DrugsTai Chi for Insomnia; WHO Guidance on GLP-1 Drugs
(MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical… (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Read More
New GLP-1 implant may help overweight pets, study underwayNew GLP-1 implant may help overweight pets, study underway
Weight loss drugs aren’t just for people anymore; They may soon be available for your furry friend. Weight loss drugs aren’t just for people anymore; They may soon be available for your furry friend.
What to know about GLP-1 drugs and muscle lossWhat to know about GLP-1 drugs and muscle loss
A recent KFF poll revealed that one in eight adults in the U.S. is currently taking a GLP-1 weight loss drug. As more people start using them, some are talking about the unexpected side effects, including muscle loss and weakness. Senior Vox correspondent Dylan Scott joins CBS News to share what patients told him. A Read More
Structure of protein reveals how breast cancer cells survive in hostile conditionsStructure of protein reveals how breast cancer cells survive in hostile conditions
UCLA scientists have characterized the structure and function of a key survival protein in breast cancer cells that helps explain how these tumors resist environmental stress and thrive in acidic, low-oxygen environments that would normally be toxic to healthy cells. The paper is published in the journal Nature Communications.
PFAS exposure may limit improvements in blood sugar after bariatric surgeryPFAS exposure may limit improvements in blood sugar after bariatric surgery
A new USC study shows teens with higher blood levels of per- and polyfluoroalkyl substances (PFAS) measured before bariatric surgery had smaller improvements in blood sugar over five years, including fasting glucose and hemoglobin A1c (HbA1c), which measures average blood sugar levels over the past 60–90 days.
GLP-1RAs shown to reduce risk of cardiovascular deathGLP-1RAs shown to reduce risk of cardiovascular death
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with chronic cardiovascular, kidney, and metabolic diseases. Those studies focused mainly on patients with singular diagnoses, but these conditions often overlap. Glucagon-like Read More
Antibody halts triple-negative breast cancer in preclinical modelsAntibody halts triple-negative breast cancer in preclinical models
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant than before.
New approach makes common breast cancer type responsive to immunotherapyNew approach makes common breast cancer type responsive to immunotherapy
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer. This subtype accounts for 70% of breast cancer cases, and despite effective treatments, it causes the highest mortality in total cases.